論文

2019年12月

[A Case of Pathological Complete Response with Neoadjuvant Chemotherapy for Advanced Rectal Cancer].

Gan to kagaku ryoho. Cancer & chemotherapy
  • Shukichi Okada
  • Hitoshi Kameyama
  • Kaoru Abe
  • Kana Tanaka
  • Hidehito Oyanagi
  • Mae Nakano
  • Hiroshi Ichikawa
  • Takaaki Hanyu
  • Kazuyasu Takizawa
  • Masato Nakano
  • Masayuki Nagahashi
  • Yoshifumi Shimada
  • Jun Sakata
  • Takashi Kobayashi
  • Toshifumi Wakai
  • 全て表示

46
13
開始ページ
2057
終了ページ
2059
記述言語
日本語
掲載種別
研究論文(学術雑誌)

A 62-year-old man was admitted with complaints of bloody stool. Colonoscopy revealed a 5 cm diameter type 2 tumor in the lower rectum close to the anal canal. Tumor biopsy indicated a well-differentiated tubular adenocarcinoma. Computed tomography revealed locally advanced rectal cancer with mesorectal lymph node metastases(cT3N1P0M0, Stage Ⅲa, JSCCR 8th). The patient was treated with neoadjuvant chemotherapy(NAC)after transverse colostomy as an anus-preserving procedure. For the NAC, 12 courses of capecitabine plus oxaliplatin(CapeOX)and bevacizumab(BV)were administered. Colonoscopy after NAC revealed that the main tumor had considerably shrunk. No malignant tissues were found on biopsy. However, rectal wall thickness remained unchanged. Therefore, response evaluation for chemotherapy indicated partial response. Intersphincteric resection(ISR)with diverting loop ileostomy was performed as an anus-preserving surgical procedure. No remnant tumor in the rectum or lymph node metastases were found upon the pathological examination of resected specimens. Ileostomy closure was performed at 6 months post-ISR. At 12 months post-ISR, the patient was well and showed no signs of recurrence. This case demonstrated that NAC with CapeOX and BV can be a promising option for treating locally advanced lower rectal cancer and preserving the anus.

リンク情報
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32157058
ID情報
  • ISSN : 0385-0684
  • PubMed ID : 32157058

エクスポート
BibTeX RIS